Owkin has announced a multi-year strategic collaboration with Bristol Myers Squibb. There are also reports of Owkin collaborating with Sanofi, with one outlet mentioning a five-year pact to license Owkin's AI technology. The nature and extent of these collaborations, and how they relate to each other, are not entirely clear.